Your GPCR Program Decisions Depend on Good Data Interpretation
- Dr. GPCR News
- Jul 17
- 4 min read
Updated: Aug 9
Welcome GPCR Fans,
In GPCR-targeted drug discovery, precision isn’t optional—it’s a requirement. But precision isn’t just about clean data; it’s about interpreting what that data means. Subtle misinterpretation can quietly derail projects, slow timelines, and waste scarce resources.
That’s why this week at Dr. GPCR, we’re focusing on the hidden risks that undermine progress and how the right frameworks can keep your pipeline moving forward.
This is a preview of what Premium Members access every week: industry insights, event updates, jobs, and classified publications—curated for scientists who need fast, actionable intelligence.
🔍 This Week in Premium: Sneak Peek
Dr. GPCR Premium Members this week gain curated, early access to:
Industry insights: GPCRs and mRNA in drug discovery; new strategies for inflammatory disease treatment; growth strategies from Tectonic Therapeutics
Upcoming events: Lab-in-the-Loop AI-powered hit discovery (July 29); 5th Transatlantic GPCR Symposium (Sept 3–4); neuroGPCR Symposium (Sept 17)
Career opportunities: Lead/Senior Researcher at St. Jude; Postdoctoral Fellow at University of Copenhagen; PhD in proteomics and GPCR signaling in cancer at CRCM
Must-read publications: AlphaFold3 benchmarking for GPCRs; new structural insights into peptide ligand activation
All curated for speed, relevance, and immediate application—only for Premium Members.
Terry’s Corner: Rethinking Affinity, A Critical Edge for Drug Hunters
One of the most persistent misconceptions in pharmacology workflows? The interpretation of high and low affinity binding sites on GPCRs.
At first glance, when a ligand binds at two different affinities in the same system, it seems logical to assume two distinct sites. But Terry Kenakin’s new Emerging Drug Hunter lecture reveals why this assumption can mislead even experienced teams.
What’s Really Going On?
Under certain experimental conditions, what appears to be a second high-affinity site may simply reflect kinetic factors—such as ligand-receptor-G protein complex formation—creating the illusion of multiple sites that aren’t physiologically relevant.
This misunderstanding leads to:
Inefficient structure-activity relationship (SAR) cycles
Wasted optimization efforts
Focus on leads that fail later in development
In this exclusive session, Kenakin gives you the frameworks needed to interpret data correctly, eliminate wasted effort, and accelerate confident decisions.
🔒 Available only in Terry’s Corner - Premium Members get an exclusive discount
Why the Myth of Multiple Affinity Sites Slows You Down
Traditional models that shaped affinity analysis were designed for simpler systems. If you’re not accounting for their limitations today, your team risks costly misinterpretations that delay optimization cycles and waste resources.
Kenakin shows exactly how to separate what matters from what misleads—practical, real-world expertise designed to help teams move faster, smarter, and with greater confidence.
Every day spent misunderstanding apparent affinity differences delays key milestones.
🗣️ “Thank you for bringing this (Principles of Pharmacology I) course with Dr. Kenakin. I wish Dr. GPCR the best for the sake of promoting more educational opportunities that are sorely needed in the field”
— Dr. GPCR University Learner
Celtarys Research Recap: Medicinal Chemistry Highlights You May Have Missed
The pace of innovation in medicinal chemistry is accelerating—and if you missed this year’s ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025, you’re already behind.
At this international meeting, leaders shared next-gen strategies shaping modern drug discovery:
Prof. Ingo Hartung: State-of-the-art design of small molecule drugs, including PROTACs
Dr. Wendy Young: Career insights and lessons from a leader in drug development and a champion for women in science
Dr. Katerina Leftheris: New technologies overcoming peptide limitations with insights from both pharma and startup environments
Lab Leadership Without Ego: A Model for R&D Success
Scientific rigor doesn’t thrive in cultures defined by micromanagement or burnout.
At Alkermes, Sokhom Pin built an in vitro pharmacology group from scratch—not just a lab, but a culture that encouraged curiosity, empowered people, and supported balance while delivering results.
His leadership principles:
Hire for attitude and team fit—not just credentials
Design workflows that enable curiosity-driven research
Support work-life balance without compromising scientific excellence
His approach didn’t just create a productive lab—it accelerated outcomes and laid the cultural foundation for the next generation of biotech innovation.
Why Dr. GPCR Premium Membership Gives You an Edge
Dr. GPCR Premium is designed for scientists who need the right intelligence, fast—without noise, distractions, or delays.
Every week, members get:
A full edition of GPCR Weekly News: jobs, events, papers, industry updates
Exclusive discounts on Terry’s Corner digital pharmacology courses
Priority access to insights from major conferences, emerging research, and expert commentary
Whether you’re a pharmacologist, biotech scientist, or team leader, Dr. GPCR Premium gives you an edge in a fast-moving field.
FAQ: What’s Included, Who It’s For, Why Now
What’s included?
The complete Weekly News digest, jobs, upcoming events, classified industry intelligence, Courses, & Conference Presentations.
Who is it for?
Scientists, drug discovery teams, and pharmacologists who need curated, career-relevant updates.
Why now?
The field is evolving rapidly. Those acting on the right insights now will define the next wave of discovery.
Don’t Fall Behind—Access the Edge You Need
Hashtags:
#GPCR #DrGPCR #BindingAffinity #Pharmacology #DrugDiscovery #LeadOptimization #TerryKenakin #EmergingDrugHunter #EfficientDiscovery #PipelineAcceleration
Comments